Please login to the form below

Not currently logged in
Email:
Password:

AZ strips Brennan of performance-related share bonus

But he still retires with a multi-million pound package

AstraZeneca's former CEO David Brenan

AstraZeneca has told its former chief executive David Brennan he will have to forfeit his share bonuses for 2011 and 2012 as part of a retirement settlement.

But he remains inline for a multi-million pound payout that includes a lump sum payment of £914,122, the equivalent of 11 months' base pay, in lieu of contractual notice, and a pension pot worth £14.8m.

Brennan's unexpected announcement earlier this year that he would be stepping down came on the same day that the company revealed first quarter profit figures had dropped by 26 per cent.

Before the announcement Brennan had been under sustained pressure from shareholders for failing to address AZ's decline in market performance.

The company's problems were fuelled mainly by patent expiries for several key drugs, including its antipsychotic treatment Seroquel and a series of stalled drug development efforts for ovarian cancerdepression and respiratory syncytial virus.

Brennan officially relinquished his responsibilities as chief executive and an executive director on June 1, after six years as the head of the pharma company, and AZ has now released details of his retirement settlement.

As part of this he has been told he will have to give up share awards worth around £4.3m that were made in 2011 and 2012 under the AstraZeneca Performance Share Plan and the AstraZeneca Investment Plan, and he has also voluntarily opted out of one other potential bonus.

“Mr Brennan informed the Remuneration Committee that he did not wish to be considered for a bonus in respect of that part of 2012 during which he was chief executive officer. The Committee determined that no such bonus would be awarded,” AstraZeneca said in a statement.

The Committee also decided not to give him a bonus for his 11-month contractual notice period, however he will still be inline for share awards based on the company's 2010 performance worth an estimated £1.5m. 

Brennan took over as chief executive at the end of 2005 from Tom McKillop who not only kept his shares but was also given a short-term performance-related bonus of £1.3m as part of his retirement payoff.

17th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
eyeforpharma

eyeforpharma is a hub for senior-level pharma executives, patient advocacy groups and other health experts to exchange ideas and stay...

Latest intelligence

Online Physician Communities
Review: diabetes tweetchat
Some of the key points from the recent #M3diabetes tweetchat held by PMLiVE and M3 Europe...
access denied
Sales reps struggle to access doctors
Doctors continue to turn away from face-to-face visits from pharma sales reps and look instead towards mobile technology for information...
Online Physician Communities
Research finds doctors are optimistic about new diabetes drugs but concerned over rationing
New data from M3 Global Research shows that clinicians buy in to the effectiveness of new diabetes therapies. However, they are concerned about rationing and believe that more resources are...